You are here

Open

Reset

NOTE: The Solicitations and topics listed on this site are copies from the various SBIR agency solicitations and are not necessarily the latest and most up-to-date. For this reason, you should visit the respective agency SBIR sites to read the official version of the solicitations and download the appropriate forms and rules.


If no search results for your keyword(s) were found, you are encouraged to review Agency omnibus solicitations for additional funding opportunities. Omnibus solicitations are structured to be broad, extensive Programmatic issuances with research areas related to the petitioning Agency and are not limited to predetermined Topics/Subtopics. If upon reviewing you have additional questions, you may consider reaching out to the respective Agency for clarification regarding acceptable proposals (https://www.sbir.gov/agency-contacts).

Displaying 21 - 30 of 158 results
  1. NIH/NIAID 131: Development of Bacteriophage for Treatment of Mycobacterial Infections

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years Background There is an urgent need for new therapeutics products for treating pulmonary diseases caused by mycobacteria. These include tuberculosis (TB), caused by Mycobacterium ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  2. NIH/NIAID 132: Novel Diagnostic Biomarker Discovery and Validation for Malaria and Select Neglected Tropical Diseases (NTDs)

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast-Track proposals will be accepted. Direct-to-Phase II proposals will NOT be accepted. Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years. Background Diagnostics in current use for malaria and specific NTDs (visceral leishmaniasis, lymphatic filariasis, onchocerciasis, schistosomiasis) do not meet the sensitivity ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  3. NIH/NIAID 133: Development of a Serological Test for Herpes Simplex Types 1 and 2 Infections

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    (Direct to Phase II proposals will not be accepted) (Fast-Track proposals will be accepted) Number of anticipated awards: 1-2 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $1,500,000 for up to 3 years Page 118 Background Over 60 million people in the U.S. have genital herpes which is caused by infection with herpes simplex virus type 1 or 2 (HSV-1, HSV-2). The WHO’s 2021 gl ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  4. NIH/NIAID 134: Alternatives to Benzathine Penicillin for Treatment of Syphilis

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast-Track proposals will be accepted Direct-to-Phase II proposals will be accepted Number of anticipated awards: 2-3 Budget (total costs): Phase I: $300,000 for up to one year; Phase II: $1,500,000 for up to 3 years Background Injectable benzathine penicillin (BPG) is currently the only CDC-recommended first line therapy for treatment of infection with Treponema pallidum (syphilis) in all populat ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  5. NIH/NIAID 135: Software or Web Services to Automate Metadata Enrichment and Standardization for Data on Infectious and Immune – Mediated Diseases

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast Track Proposals will be accepted. Direct-to-Phase II will be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $ 300,000 for up to 1 year. Phase II: $ 1.5 million for up to 3 years. Page 120 Background The ability of innovative data science approaches to accelerate research on infectious and immune-mediated diseases highly depends on the availability of high-quality, ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  6. NIH/NIAID 136: Software or Web Services to Re-Represent Existing Scientific Data and Knowledge into a Knowledge Graph Format

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Fast Track Proposals will be accepted. Direct-to-Phase II will be accepted. Number of anticipated awards: 1-3 Budget (total costs): Phase I: $ 300,000 for up to 1 year. Phase II: $ 1.5 million for up to 3 years. Background Scientific research produces more data and knowledge than ever before and it is becoming increasingly challenging for researchers to digest and analyze the data to derive new kn ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  7. NIH/NHLBI 115: Clinical Instrument for Para-Hydrogen (pH2) Based Signal Amplification by Reversible Exchange (SABRE) for Hyperpolarizing 13C-Pyruvate and Other Probes for MRI Imaging

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Budget and number of awards: Fast-Track proposals will be accepted. Direct-to-Phase II proposals will be accepted Number of anticipated awards: 1 Phase I, 1 Phase II Budget (total costs per award): Phase I: $350,000 for 12 months; Phase II: $3,000,000 for 2 years It is strongly suggested that proposals adhere to the above budget amounts and project periods. Proposals with budgets exceeding the abo ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  8. NIH/NIMH 001: Point-of-Care HIV Viral Load and Drug Adherence Assays

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    (Fast-Track and Direct to Phase 2 proposals will not be accepted) Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $2,000,000 for up to 2 years. Background According to the Centers for Disease Control and Prevention (CDC), HIV remains a significant public health challenge both in the United States and globally. In the United States, an estimated ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  9. NIH/NIMH 002: Development of novel In-vitro and In-vivo Models to support NeuroHIV Research

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    (Fast-Track and Direct to Phase 2 proposals will not be accepted) Number of anticipated awards: 1-3 Budget (total costs): Phase I: $300,000 for up to 1 year; Phase II: $2,000,000 for up to 2 years. Background Central Nervous System complications associated with HIV continues to persist in people with HIV (PWH) despite effective Page 128 Antiretroviral therapy (ART). Although excellent virologic co ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesNational Institutes of Health
  10. CDC/NCEZID 031: Development of SHERLOCK Assay for Detection of High Threat Orthopoxviruses

    Release Date: 08-25-2023Open Date: 08-25-2023Due Date: 11-14-2023Close Date: 11-14-2023

    Phase I SBIR proposals will be accepted. Fast-Track proposals will not be accepted. Phase I clinical trials will not be accepted. Number of anticipated awards: 1 Budget (total costs): Phase I up to $243,500 for up to 6 months; Phase II of up to $1,927,828 and a Phase II duration of up to 2 years. PROPOSALS THAT EXCEED THE BUDGET OR PROJECT DURATION LISTED ABOVE MAY NOT BE FUNDED. Background Point ...

    SBIRPhase I/Phase IIDepartment of Health and Human ServicesCenters for Disease Control and Prevention
US Flag An Official Website of the United States Government